ArticleAmerican journal of translational research2021
The therapeutic effect of Healaflow in glaucoma surgery.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 7 citations in OpenAlex.
- The Role of Biodegradable Collagen Matrices in Glaucoma Filtration Surgery: Practical Considerations in the Post-Ologen Era.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Optimizing Filtration Surgery Procedures in African-Derived Populations: Trabeculectomy and Preserflo.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Effect of Subconjunctival Healaflow in Filtrating Surgery with Preserflo MicroShunt in Primary Open Angle Glaucoma.Journal of clinical medicine · 2025Article
- Reducing Postoperative Needling in XEN63Journal of clinical medicine · 2025Article
- Efficacy and Safety of Ab Externo Open Conjunctiva XENJournal of clinical medicine · 2025Article
- Review
- XEN45 Gel Stent Combined with Healaflow Injectable Viscoelastic Implant.Case reports in ophthalmological medicine · 2023Article
- Advances in biomaterials as a retinal patch for the repair of rhegmatogenous retinal detachment.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the clinical effectiveness of Healaflow in primary angle-closure glaucoma surgery.
methodsFrom August 2018 to July 2019, 100 primary angle-closure glaucoma patients admitted to our ophthalmology department were divided into a control group (trabeculectomy alone) and an observation group (trabeculectomy + Halver), with 50 patients in each group, and 53 eyes in the control group and 56 eyes in the observation group. All the patients were followed up for half a year. The vision, intraocular pressure, bleb morphology, efficacy, and adverse reactions were evaluated.
resultsThere was no significant difference in the visual acuity between the two groups of patients during the follow-up (P > 0.05). The intraocular pressure levels in the two groups of patients during the follow-up were significantly lower than they were before the treatment (P < 0.05), and the difference in the intraocular pressure levels between the 6th month postoperative groups was significant (P < 0.05). During the last follow-up, 45 eyes in the control group developed functional filtration blebs, and 8 eyes had non-functioning filtration blebs. There were 55 functional filtration blebs and 1 non-functional filtration bleb in the observation group (
conclusionHealaflow is of great value in maintaining functional filtration blebs and in controlling and stabilizing intraocular pressure. It is safe and reliable in clinical application, and it helps to reduce the unstable intraocular pressure after glaucoma surgery caused by scar adhesions in the filtration channel.
Indexed as
Identifiers
34540102PMC8430195W3201113248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.